DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksSchließen
Referenz
Llovet JM, Decaens T, Raoul J-L , et al.
Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the phase 3 BRISK-PS study.
Abstract presented at: 47th Annual Meeting of the European Association for the Study of the Liver; April 18–22, 2012; Barcelona, Spain
Bibliographische Angaben herunterladen
Suchen in:
Für die Inhalte der Internetseiten anderer Anbieter übernehmen wir keine Verantwortung.